A permanent global mpox vaccine stockpile launches after 2022's access failures
Gavi is funding a standing mpox vaccine stockpile, coordinated by the same group that manages emergency supplies for cholera, yellow fever and Ebola, to avoid repeating the 2022 access gap.
WHO and partners announced on 2 September that a standing global stockpile of mpox vaccines has been established, a long-term mechanism intended to give any country faster access to doses during an outbreak [s1]. The stockpile launched on 27 August and is set to begin operations later in September [s1].
The initiative is a direct response to a failure the world watched unfold twice. When mpox spread globally in 2022, lower-income countries were, in Gavi's own account, "left behind" on vaccine access, and a repeat during the 2024 emergency prompted an ad hoc scramble for doses [s1]. The new stockpile is an attempt to institutionalise the fix rather than improvise it each time.
How the mechanism is built
The financing and the plumbing come from established bodies rather than a new agency. The stockpile was approved by the Board of Gavi, the Vaccine Alliance, in 2025, is funded by Gavi, and is coordinated by the International Coordinating Group (ICG) on Vaccine Provision [s1]. The ICG's partners are the International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières, UNICEF and WHO [s1].
That choice of home is the substance of the announcement. The ICG was created in 1997 after major meningitis outbreaks in Africa, and its core mandate has been to manage emergency vaccine stockpiles and ensure equitable access to licensed vaccines for cholera, meningitis, yellow fever and Ebola virus disease during outbreaks [s1]. Adding mpox extends a model that already exists rather than inventing one — the point WHO's leadership emphasised, describing an approach "that has proven successful for managing other emergency vaccines" [s1]. The new stockpile continues the work begun under the Access and Allocation Mechanism that WHO and partners set up in 2024 during the last mpox Public Health Emergency of International Concern [s1].
Why mpox still needs an outbreak-response tool
Mpox has not receded into the background. Between 1 January 2022 and 31 July 2026, 145 countries and territories reported 190,683 confirmed cases and 529 deaths, with two-thirds of reported cases occurring in the African Region [s1]. The virus spreads mainly through close physical contact, including sexual contact, and animal-to-human transmission continues in parts of Africa, which keeps seeding new outbreaks [s1]. It can cause severe disease, particularly in children and people with weakened immune systems [s1].
The biology is also more complicated than a single-vaccine campaign implies. There are two distinct clades of the monkeypox virus — clade I, with subclades Ia and Ib, and clade II, with subclades IIa and IIb — and the global outbreak that began in 2022 was driven by clade IIb, even as clade I outbreaks grew separately in the Democratic Republic of the Congo and neighbouring countries [s2]. MSF noted that the coexistence of different variants affecting different populations is precisely why a coordinated allocation mechanism, rather than country-by-country deals, is needed [s1].
Vaccines are useful here partly because of timing. Mpox vaccination can work as post-exposure prophylaxis, but the window is short: WHO advises giving the vaccine within four days of contact for the best chance of preventing disease, or up to 14 days if no symptoms have appeared [s2]. A stockpile that can move doses quickly is therefore not a convenience but a condition of the vaccine doing its job.
What to watch
The announcement is a commitment about supply architecture, not a claim about doses delivered. Its value will be measurable only the next time an outbreak flares — whether a country facing a clade I or clade IIb surge can draw doses in days rather than negotiating for weeks. Gavi framed the goal plainly: that "any country in the world — not just those with the ability to pay the most" should be able to use the tool [s1].
For readers, the useful frame is that this is a global-health-financing story as much as a vaccine one. The scientific tools for mpox already exist; what the 2022 and 2024 outbreaks exposed was a distribution and financing gap. Whether a standing, Gavi-funded stockpile closes that gap is the open question the coming outbreak season will answer.
Sources
- [s1] World Health Organization, "Global initiative launched to improve access to mpox vaccines," 2 September 2026.
- [s2] World Health Organization, "Mpox" (fact sheet), accessed 2 September 2026.
Sources
- Global initiative launched to improve access to mpox vaccines — World Health Organization , September 2, 2026
- Mpox (fact sheet) — World Health Organization , September 2, 2026
More on
Four in ten hospitalised mpox patients developed eye disease, a Congolese cohort finds
In South Kivu, ophthalmologists examined 310 patients with confirmed clade Ib mpox at four time points. Periorbital lesions and severe acute malnutrition tripled the risk of ocular involvement.
A hospital-linked mpox outbreak in Pakistan is killing infants at a 28% case fatality rate
WHO's latest mpox report shows global case counts holding steady, but flags a Sindh province cluster where nearly all deaths were in babies under six months old.
A recombinant mpox virus turned up twice, and the routine test called it two clades
WHO reports two cases of a monkeypox virus carrying genetic material from both clade Ib and clade IIb. The finding that matters for surveillance is that clade differentiation PCR missed it both times.
Clade Ib mpox spread poorly inside Burundi households — except to children
A prospective cohort of 88 index cases and 432 household contacts found a secondary attack rate of 6.15%, three times higher in under-15s. The estimated R0 inside households was 0.30.